Literature DB >> 2049259

The effects of cimetidine and ranitidine on the pharmacokinetics of cifenline.

J W Massarella1, T M Defeo, J Liguori, S Passe, K Aogaichi.   

Abstract

Twelve healthy subjects completed an open single dose study to evaluate the effect of co-administration of cimetidine and ranitidine on the pharmacokinetics of cifenline. Each subject received a single 160 mg dose of cifenline alone, in combination with cimetidine (300 mg four times daily), and with ranitidine (150 mg twice daily). The H2-receptor antagonists were given with breakfast 1 h prior to cifenline dosing and continuing for 48 h. Co-administration of cimetidine significantly increased Cmax (27%) and AUC (44%) and prolonged the half-life (30%) of cifenline. There were no differences in these parameters when ranitidine was co-administered with cifenline. The results of this study suggest that cimetidine, but not ranitidine, lowers the clearance of cifenline by inhibition of hepatic oxidative metabolism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049259      PMCID: PMC1368338          DOI: 10.1111/j.1365-2125.1991.tb05566.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Relative and absolute bioavailability of cibenzoline capsules and tablets in healthy subjects.

Authors:  J Massarella; T Silvestri; A Lin
Journal:  J Pharm Sci       Date:  1986-09       Impact factor: 3.534

2.  Altered pharmacokinetics of oral flecainide by cimetidine.

Authors:  T B Tjandra-Maga; A van Hecken; P van Melle; R Verbesselt; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

3.  Reduced steady-state plasma concentrations of chlorpromazine and indomethacin in patients receiving cimetidine.

Authors:  C A Howes; T Pullar; I Sourindhrin; P C Mistra; H Capel; D H Lawson; W J Tilstone
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Cimetidine inhibition of ethmozine metabolism.

Authors:  J Biollaz; O Shaheen; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

5.  Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites.

Authors:  L B Slusher; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

Review 6.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

7.  Age and cibenzoline disposition.

Authors:  R K Brazzell; M M Rees; K C Khoo; A J Szuna; D Sandor; J Hannigan
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

Review 8.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

9.  Determination of cibenzoline in plasma and urine by high-performance liquid chromatography.

Authors:  M R Hackman; T L Lee; M A Brooks
Journal:  J Chromatogr       Date:  1983-04-08

10.  Alteration of pentoxifylline pharmacokinetics by cimetidine.

Authors:  V F Mauro; L S Mauro; J H Hageman
Journal:  J Clin Pharmacol       Date:  1988-07       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.